drugset
drugset / Trial / NCT06682000

Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension

NCT06682000 ↗

Phase 3 Completed 192 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy

Timeline

Start
2025-01-20
Primary completion
2025-10-02
Completion
2025-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject DWC202314 Unknown — Oral
Background DWC202404 Unknown — Oral

Indications

essential hypertension